Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid

Journal of Affective Disorders
Madhav A NamjoshiAlan Breier

Abstract

The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder. Patients with bipolar I disorder, were randomized to receive either olanzapine (5-20 mg) added to mood stabilizer therapy (n=224), or placebo added to mood stabilizer therapy (n=112) for 6 weeks. Changes in clinical outcomes over 6 weeks were measured by the Young Mania Rating Scale (Y-MRS) and the Hamilton Rating Scale for Depression (HAM-D). Quality of life was measured by the Lehman Brief Quality of Life Interview (QLI). Patients treated with olanzapine added to mood stabilizers, experienced significantly greater mean clinical improvements from baseline on both the Y-MRS and the HAM-D compared to those treated with placebo added to mood stabilizers. Over 6 weeks, patients treated with olanzapine added to mood stabilizers had significantly greater mean improvements from baseline on five of the nine subjective scales on the QLI, compared to patients treated with placebo added to mood stabilizers. Changes in scores on the subjective scales of the QLI were more strongly correlated to changes in depres...Continue Reading

References

Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Dec 1, 1967·The British Journal of Social and Clinical Psychology·M Hamilton
Apr 1, 1983·Archives of General Psychiatry·A F Lehman
Mar 1, 1997·The Journal of Nervous and Mental Disease·J RussoD Patrick
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

Aug 30, 2006·Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors·David A WassermanSharon M Hall
Mar 23, 2010·BMC Psychiatry·Doron SagmanElizabeth Brunner
Jan 18, 2013·Depression Research and Treatment·Homayoun Amini, Vandad Sharifi
Jun 14, 2005·Bipolar Disorders·Eduard Vieta, Jose M Goikolea
Feb 15, 2012·Bipolar Disorders·Waguih William IsHakRose Hanna
Sep 19, 2017·Psychological Medicine·E MortonL N Yatham
Jun 15, 2005·Bipolar Disorders·Lakshmi N YathamUNKNOWN Canadian Network for Mood and Anxiety Treatments
Oct 1, 2006·Expert Review of Pharmacoeconomics & Outcomes Research·Michael BerkPhilippe Conus
Nov 3, 2004·CNS Spectrums·Daniel Souery, Karel Van der Auwera
Oct 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Rogier M KlokMaarten J Postma
Apr 6, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Erin E MichalakRaymond W Lam
Nov 18, 2005·Health and Quality of Life Outcomes·Erin E MichalakRaymond W Lam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here